Big data on way to enabling 'zero defect' glass tubing
New perfeXion system, which generates around 100,000 data tags/min, makes an important contribution to quality assurance for downstream post-processing steps at the beginning of the value chain.
Schott is integrating a specially developed big data solution into its pharmaceutical tubing production, replacing statistical sample-based quality assurance with 100 percent on-line measurement. With the new IT-based process called perfeXion, process- and product-quality data of each individual glass tube is collected online and in real-time – an innovation that sets new standards in the pharmaceutical glass industry.
Making accurate glass tubes for the pharmaceutical industry is no light feat: at several metres per second, a virtually endless glass tube comes from the melt at over 1,600 °C and is drawn over a rotating mandrel. By making adjustments to the drawing speed and the air supply, wall thickness and tube diameter can be precisely determined down to the hundredth of a millimeter. A few metres further down the line, the cooled glass section is then cut into roughly 1.50-m-long pieces. From these glass tubes, converters can later manufacture pharmaceutical containers such as vials and syringes. Thanks to a unique big data approach, Schott is now able to measure 100% of every single glass tube in production. This data also enables for post-processing steps to be efficiently aligned with the tubing quality. With big data, the international technology group is creating a new industry standard and raising the quality of pharmaceutical glass production to a new level.
Instead of selecting a few glass tubes from each batch for statistical quality control, the new perfeXion system measures the entire glass tube many times over as it is drawn from the melt. Lasers recognize deviations in diameter and wall thickness, for example, and camera and IR inspection systems can even detect the smallest inclusions in the glass. Around 100,000 data tags are generated every minute. An integrated IT system, evaluating the continuous glass tube with real-time data measurements, calculates incidents of imperfection with such precision that it can later differentiate corresponding individual tubes which can then be sorted out. Each tube is checked again at its completion.
The system’s development took several years. Analysing a curved tube surface zooming down a production line was a particularly difficult challenge. The effort, however, has paid off – not least because the data analysis is a source of insight into how production can be further optimized.
Every year, Schott produces about 150,000 tons of glass tubing, most of which is destined for pharmaceutical packaging such as vials and syringes. Thanks to the new perfeXion approach, quality data can be traced back more detailed, not only by Schott but also the companies at subsequent steps in the value chain. “There comes a particular responsibility being a pharmaceutical industry supplier, and traceability is a major issue in the industry,” says Dr Patrick Markschläger, Executive Vice President at Schott Tubing. “By gathering information on each individual glass tube, we’ve already made an important contribution to quality assurance for downstream post-processing steps at the very beginning of the value chain.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance